T. Rowe Price Associates
CMPX icon

T. Rowe Price Associates’s Compass Therapeutics CMPX Stock Holding History

T. Rowe Price Associates’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527K Buy
99,522
+29,034
+41% +$168K ﹤0.01% 2432
2025
Q4 		$379K Buy
70,488
+13,900
+25% +$64.2K ﹤0.01% 2523
2025
Q3 		$199K Buy
56,588
+9,646
+21% +$30.5K ﹤0.01% 2795
2025
Q2 		$123K Hold
46,942
– – ﹤0.01% 2852
2025
Q1 		$90K Hold
46,942
– – ﹤0.01% 2841
2024
Q4 		$69K Buy
46,942
+11,326
+32% +$18.8K ﹤0.01% 2890
2024
Q3 		$66K Buy
35,616
+7,504
+27% +$9.35K ﹤0.01% 2892
2024
Q2 		$29K Buy
28,112
+4,057
+17% +$5.92K ﹤0.01% 2897
2024
Q1 		$48K Buy
24,055
+700
+3% +$1.21K ﹤0.01% 2876
2023
Q4 		$37K Buy
23,355
+2,892
+14% +$5K ﹤0.01% 2842
2023
Q3 		$41K Buy
20,463
+1,942
+10% +$4.8K ﹤0.01% 2797
2023
Q2 		$59K Buy
+18,521
New +$58.2K ﹤0.01% 2784

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's CMPX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Compass Therapeutics (CMPX) stake by 41% in Q1 2026, buying an estimated $168K and bringing the position to 99,522 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #2432.

T. Rowe Price Associates first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • T. Rowe Price Associates held 99,522 shares of Compass Therapeutics worth $527K as of Q1 2026.
  • T. Rowe Price Associates bought 29,034 Compass Therapeutics shares in Q1 2026, an estimated $168K.
  • Compass Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2432 holding.
  • T. Rowe Price Associates first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.